MEGHAN MULLINS: Open Payments
NPI 1215307459 · BRISTOL, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,348 in 55 payments from 17 companies in 2025. Trend: 2023 $473 · 2024 $531 · 2025 $1,348
Food & beverage: $1,348
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $333 |
| Lilly USA, LLC | 8 | $241 |
| Novo Nordisk Inc | 9 | $222 |
| ABBVIE INC. | 5 | $104 |
| PFIZER INC. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $68 |
| Eisai Inc. | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 4 | $40 |
| Amgen Inc. | 2 | $30 |
Products named: BREZTRI, Ozempic, ZEPBOUND, MOUNJARO, UBRELVY, CAPLYTA, XIFAXAN, Leqembi.
Industry payments across TN — which companies pay providers there.
